Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

5-Amino-1MQ: Regulatory Status

Current legal and regulatory status for 5-Amino-1MQ across jurisdictions. This page reflects the most recent verified information and is updated as regulatory actions occur.

Back to 5-Amino-1MQ overview

United States

Compoundable (503A)

Prescription required

Compounding status: available through compounding pharmacies and research suppliers. WADA: not listed. no regulatory development program; sold as research compound

Last verified:

What This Means

Compoundable does not mean FDA approved.

5-Amino-1MQ is available through licensed 503A compounding pharmacies with a physician's prescription. This is a regulatory pathway, not an endorsement of efficacy for any specific indication. All use is off-label.

Reclassification is not the same as FDA approval.

Even if 5-Amino-1MQ moves to Category 1, it remains an off-label therapeutic that requires physician supervision. Category 1 means it can be compounded under section 503A — it does not confer approved-drug status.

5-Amino-1MQ Overview

Uses, benefits, evidence, and monitoring.

Contraindications

Safety profile and drug interactions.

Evidence Summary

Clinical trial data and evidence tiers.